The pharmaceutical industry has largely overlooked the benefits of recovering solvents on-site, preferring instead to rely on the repurchase of virgin solvents, or the offsite recovery of solvents using third-party processors.
Currently, many manufacturers rely on toll processors to perform recovery of solvents off-site. In addition to the transportation hazards, because the toll processor can be dealing with a number of different materials for different customers, the residue that remains in the equipment could cause cross contamination of the recovered solvents.
This practice results in other liabilities. While recovery and recycling of solvents during the manufacturing process on-site is more easily controlled, transporting solvents over public roads and railways can result in hazardous material spills, thereby contaminating the environment and putting the public at risk. The owner bears the risk for such a spill as well.
Other solutions for disposal such as incineration may be less attractive from an environmental standpoint.
There is also an economic downside. Resorting to disposal of used solvents and repurchase of virgin solvents is an expensive process, and many pharmaceutical companies are leaving significant amounts of money on the table. The return on investment for designing and installing an on-site solvent recovery unit can show an ROI of under two years and often can pay for itself in less than one year. Distillation and Liquid-Liquid Extraction columns, installed on modularly constructed skids, have been the solution of choice for many pharmaceutical companies that, today, are focused on finding savings in ever more remote corners of their facilities.
As concerns over climate change become increasingly pressing, pharmaceutical companies are conducting extensive environmental audits across virtually every aspect of their business. Regulatory demands are also becoming increasingly stringent for both environmental (incineration method) and over-the-roadway hazards (toll processor recovery), both of which affect the way in which solvent disposal/recovery is currently handled.
There is also significant public pressure being brought to bear on pharmaceutical companies to demonstrate their commitment to corporate responsibility in this regard. This is a matter often highlighted in corporate annual reports. As a result, facility-based engineering teams, corporate engineering and public-facing corporate executive teams are pulling together to address these challenges.
Solvent recovery and recycling systems are one way these companies can mitigate their impact on the environment, as well as improve safety standards and produce product more economically.